Oculis to Present DME Research and Pipeline Updates at ARVO 2026 Annual Meeting

Key Takeaways

• Oculis will present DME AWARE Delphi Study findings on unmet needs in diabetic macular edema management at ARVO 2026
• Research highlights the critical need for non-invasive therapeutic options for DME patients
• CEO Riad Sherif will provide corporate pipeline updates and upcoming development milestones at Eyecelerator

---

Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company specializing in ophthalmology treatments, announced it will present key research findings and corporate updates at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in 2026.

DME Research Presentation

Dr. Baruch Kuppermann, M.D., Ph.D., will present the latest findings from the DME AWARE Delphi Study, which examines unmet medical needs in diabetic macular edema (DME) management. The study’s results emphasize the urgent need for non-invasive therapeutic options for DME patients, potentially reshaping treatment approaches for this vision-threatening condition.

Diabetic macular edema affects millions of diabetes patients worldwide and remains a leading cause of vision loss. Current treatment options often require invasive procedures, creating a significant gap in patient care that non-invasive alternatives could address.

Corporate Pipeline Updates

Oculis CEO Dr. Riad Sherif will deliver a comprehensive corporate update at the Eyecelerator event, detailing the company’s drug development pipeline and upcoming clinical milestones. This presentation will provide investors and healthcare professionals with insights into Oculis’ strategic direction and potential market opportunities.

Market Implications

The ARVO presentations underscore Oculis’ commitment to addressing critical unmet needs in ophthalmology. With the global diabetic retinopathy market projected to grow significantly, innovative DME treatments could represent substantial commercial opportunities.

The company’s focus on non-invasive therapeutic solutions aligns with growing demand for patient-friendly treatment options that reduce healthcare system burden while improving outcomes.

Looking Ahead

These presentations at ARVO 2026 will likely influence Oculis’ future development priorities and provide valuable data for regulatory discussions. The ophthalmology community will closely monitor how these findings translate into clinical development programs and potential new treatment paradigms for DME patients.

---

Frequently Asked Questions

What is diabetic macular edema (DME)?

DME is a diabetes complication where fluid accumulates in the macula, the central part of the retina, potentially causing vision loss or blindness if left untreated.

When will Oculis present at ARVO 2026?

Specific presentation dates have not been announced, but the ARVO Annual Meeting typically occurs in late spring, with Oculis scheduled to present DME research findings and corporate updates.

How could non-invasive DME treatments benefit patients?

Non-invasive treatments could eliminate the need for eye injections or surgical procedures, reducing patient discomfort, treatment burden, and potential complications while improving accessibility to care.